Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

BACKGROUND: The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those proteasome inhibitors indicate the need for a new generation of drugs. Therefore, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jonghoon, Park, Eok, Jung, Cheol-Kyu, Kang, Seung-Wan, Kim, Byung Gyu, Jung, Youngjoo, Kim, Tae Hun, Lim, Ji-Young, Lee, Sung-Eun, Min, Chang-Ki, Won, Kwang-Ai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806471/
https://www.ncbi.nlm.nih.gov/pubmed/27012957
http://dx.doi.org/10.1186/s12885-016-2285-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806471/
https://www.ncbi.nlm.nih.gov/pubmed/27012957
http://dx.doi.org/10.1186/s12885-016-2285-2

Ejemplares similares